<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT20191012045067N3</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2021-02-07</date_registration>
      <primary_sponsor>Vice Chancellor for Research, Zahedan University of Medical Sciences</primary_sponsor>
      <public_title>the effectiveness  of mouth wash skin fruit pomegranate extract formulation in the treatment of patients with recurrent aphthous</public_title>
      <acronym></acronym>
      <scientific_title>Evaluation of the effectiveness  of mouth wash containing skin fruit pomegranate extract formulation in the treatment of patients with recurrent aphthous stomatitis</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2020-11-30</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>30</target_size>
      <recruitment_status>Complete</recruitment_status>
      <url>https://irct.ir/trial/53663</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Randomized, Blinding: Double blinded, Placebo: Used, Assignment: Parallel, Purpose: Health service research, Other design features: effectiveness  of mouth wash containing skin fruit pomegranate extract formulation in the treatment of patients with recurrent aphthous stomatitis, Randomization description: Qualified persons with recurrent aphthous stomatitis in study were randomly divided according to coming time into three groups of pomegranate peel extract mouthwash consumer, placebo and corticosteroid chemical medicine.
In this way that the first 10 patients who were qualified of entering study and willing to cooperate entered to study as pomegranate peel mouthwash consumers. 
After a seven-day course of treatment, the second 10 patients who were qualified and willing to cooperate were evaluated and treated as placebo group.
And then again after seven days 10 other patients who were qualified and willing to cooperate were studied to take corticosteroid medicine, Blinding description: The participant and analyzer do not know the type of consumables and the consumables are numbered as 1 , 2.</study_design>
      <phase>N/A</phase>
      <hc_freetext>the effect of mouth wash containing in recurrent aphthous stomatitis treatment.</hc_freetext>
      <i_freetext>Intervention 1: Intervention group:People with recurrent aphthous ulcer  use mouth wash containing Pomegranate peel extract 4 times a day for 5 days (The patient  asked to spray the mouthwash containing pomegranate peel extract four times a day (one hour before meals and twenty minutes before bedtime) once or twice for five days and half  hour after using the drug. Avoid eating and drinking. The person  asked to dry the wound and then spray the drug once or twice). Intervention 2: Control group: :People with recurrent aphthous ulcer  use placebo 4 times a day for 5 days(The patient  asked to spray the mouthwash containing water(placebo) four times a day (one hour before meals and twenty minutes before bedtime) once or twice for five days and half  hour after using the drug. Avoid eating and drinking. The person  asked to dry the wound and then spray the drug once or twice). Intervention 3: Intervention  People with recurrent aphthous ulcer  use corticosteroid    4 times a day for 5 days(The patient  asked to spray the mouthwash containing corticosteroid (teriamcinolon ) four times a day (one hour before meals and twenty minutes before bedtime) once or twice for five days and half  hour after using the drug. Avoid eating and drinking. The person  asked to dry the wound and then spray the drug once or twice).</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan>Yes - There is a plan to make this available</results_IPD_plan>
      <results_IPD_description>What will be shared:
manuscript

When:
2 year

To whom:
researcher

Conditions:
treatment

Where to obtain:
internal site

How to obtain:
search

Comments:
</results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>Masoomeh Shirzaiy</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Azadegan</address>
        <city>Zahedan</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>9817699693</zip>
        <telephone>+98 54 3344 1824</telephone>
        <email>shirzaiy@gmail.com</email>
        <affiliation>Zahedan University of Medical Sciences</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>Masoomeh Shirzaiy</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Azadegan</address>
        <city>Zahedan</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>9817699693</zip>
        <telephone>+98 54 3344 1824</telephone>
        <email>shirzaiy@gmail.com</email>
        <affiliation>Zahedan University of Medical Sciences</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iran (Islamic Republic of)</country2>
    </countries>
    <criteria>
      <inclusion_criteria>The existence of 1-5 wounds less than 24h                                  size of less than 10mm (if there is more than one wound, the average diameter of all wounds will prevail),                                    the pain in the affected area,                                                                           the age above 18 years,                                                                              lack of history of  drug hypersensitivity,                                                                  non pregnant and no lactation ,                                                                        Lack of history of systemic disease, non-steroid anti-inflammatory medication or oral antihistamines one month before entering the study,                                                                                                           lack of treatment with systemic or immunosuppressive medications a month before entering the study,                                            treatment of wounds with any drug before entering Study,                               lack of treatment with systemic antibiotics 2weeks before entering the study,                                                                                   the absence of adjacent trauma ulcers caused by sharp tooth edges, broken healing, orthodontic appliance or denture prosthesis</inclusion_criteria>
      <agemin>18 years</agemin>
      <agemax>no limit</agemax>
      <gender>Both</gender>
      <exclusion_criteria>No attend  of  person with recurrent aphthous stomatitis in fallow up period</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code>K12.0</hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword>Recurrent oral aphthae</hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Treatment - Drugs</i_code>
      <i_code>Placebo</i_code>
      <i_code>Treatment - Drugs</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>Intervention group:People with recurrent aphthous ulcer  use mouth wash containing Pomegranate peel extract 4 times a day for 5 days (The patient  asked to spray the mouthwash containing pomegranate peel extract four times a day (one hour before meals and twenty minutes before bedtime) once or twice for five days and half  hour after using the drug. Avoid eating and drinking. The person  asked to dry the wound and then spray the drug once or twice)</i_keyword>
      <i_keyword>Control group: :People with recurrent aphthous ulcer  use placebo 4 times a day for 5 days(The patient  asked to spray the mouthwash containing water(placebo) four times a day (one hour before meals and twenty minutes before bedtime) once or twice for five days and half  hour after using the drug. Avoid eating and drinking. The person  asked to dry the wound and then spray the drug once or twice)</i_keyword>
      <i_keyword>Intervention  People with recurrent aphthous ulcer  use corticosteroid    4 times a day for 5 days(The patient  asked to spray the mouthwash containing corticosteroid (teriamcinolon ) four times a day (one hour before meals and twenty minutes before bedtime) once or twice for five days and half  hour after using the drug. Avoid eating and drinking. The person  asked to dry the wound and then spray the drug once or twice)</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>Recurrent aphthous stomatitis. Timepoint: Day Zero, second, seventh after the start of  treatment. Method of measurement: Visual Analogue Scale,Periodontal probe.</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome></sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Vice Chancellor for Research, Zahedan University of Medical Sciences</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2020-11-01</approval_date>
        <contact_name>Zahedan University of Medical Science</contact_name>
        <contact_address>Azadegan Zahedan Sistan-va-Balouchestan Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
